Weekly intelligence on AI reshaping pharma and biotech — for the people making the decisions. Short, opinionated, written from inside the field.
Medra's Physical AI Lab pairs a multi-agent reasoning layer with DARPA funding and round-the-clock autonomous operation, reframing who generates AI training data in biology. Plus: RQ Bio's $115M flu antiviral Series A, why China — not the FDA — rattled BIO 2026, virtual-cell scaling laws, and The Onion Desk.
Medra unveiled its 'AI Experimentalist' — the reasoning layer of its Physical AI Scientist platform — at a 38,000 sq ft lab running continuously since April, with DARPA already funding the work. The pitch isn't efficiency: autonomous labs generating closed-loop perturbation data may become AI biology's cheapest training-data source. Also: RQ Bio's $115M Series A for a long-acting flu prophylactic, and BIO 2026's quietly alarming signal — BIOSECURE targets manufacturing while China's scientific competition advances on a different axis entirely.
At Fortune Brainstorm Tech, NVIDIA's healthcare chief reframes AI drug discovery's core constraint as regulatory acceptance, not scientific capability. Plus: Novartis expands its molecular-glue AI deal to $1.4B, Sanofi locks in Owkin for five years, and The Onion Desk.
NVIDIA's Kimberly Powell made the case for open-source biology foundation models as shared infrastructure at Fortune Brainstorm Tech — and reframed the central bottleneck in AI drug discovery as FDA regulatory acceptance, not scientific capability. Also: Novartis expanded its Orionis molecular-glue collaboration to $1.4B, doubling down on AI-navigated undruggable target space, and Sanofi committed five years to Owkin's autonomous agentic platform across R&D workflows.
Sanofi becomes the second major pharma in three weeks to license Owkin's K Pro. BMS is now counting the bill on its 30,000-seat Claude rollout. Plus: 'first AI drug in the clinic' unpacked, the AI-funding bifurcation, and the Onion Desk.
Sanofi signed a five-year K Pro license — the same Owkin agentic platform AstraZeneca adopted three weeks earlier — in what looks less like a coincidence and more like a market. The lead story is what that licensing pattern signals about strategy versus ownership. Also this week: BMS is the first company to publicly address enterprise-AI cost management at 30,000-seat scale, and the 'first AI drug in the clinic' headline collapses under its own fine print.
A $200M Brain Health Accelerator division applies the institute's cell-type atlases to gene therapies for Alzheimer's, Parkinson's, Huntington's, and ALS. Plus: Mayo AI at ASCO, an ex-Palantir team building pharma AI orchestration, and the week's autonomous-research debate.
The Allen Institute launched a $200M Brain Health Accelerator to channel two decades of cell-type atlas work into cell-type-specific gene therapies for four neurodegenerative diseases. A rare nonprofit-to-developer transition and a signal that CNS competition is shifting from target discovery to targeting precision. Also: Mayo AI normalises at ASCO, Perceptic raises $12M for pharma workflow orchestration, and the sector debates what "autonomous scientific research" actually means.
BMS deploys Claude Enterprise across 30,000+ employees as the unified agent layer. DeepMind's Co-Scientist and FutureHouse's Robin clear Nature peer review the same week Edison Scientific lands at Incyte. Plus: the EU AI Act high-risk draft, Helio × Syneos, and a Benchling adoption snapshot.
Bristol Myers Squibb went enterprise-wide on Claude — 30,000+ employees, agent layer rather than chatbot, multi-vendor by design. The same week, two AI-scientist systems (DeepMind's Co-Scientist and FutureHouse's Robin) cleared Nature peer review and FutureHouse's commercial spinout Edison landed at Incyte. Also: the EU AI Act draft high-risk guidelines, Helio × Syneos as a deployment pattern, and a Benchling snapshot of where biotech AI adoption actually sits.
Owkin's K Pro goes live inside AstraZeneca's competitive intelligence workflows. The FDA finishes consolidating 40+ systems into HALO and ships Elsa 4.0. Plus: the cell-free expression race, UVA's open drug-design suite, and four dispatches from The Onion Desk.
AstraZeneca and Owkin deployed K Pro — autonomous agents working inside strategy and competitive intelligence, not the lab. The FDA simultaneously finished consolidating 40+ data systems into HALO and upgraded Elsa to version 4.0, making AI-assisted review the default rather than the exception. Also this week: two competing cell-free expression deals in seven days signal a real market, UVA released an open diffusion-based drug-design suite, and The Onion Desk has notes.
The UK's OpenBind initiative takes aim at the structural data gap that's quietly limited AI drug discovery since AlphaFold. Also: the FDA's AI-triage inspection pilot, Novo's enterprise OpenAI bet, and Insilico's empirical case against general-purpose models.
OpenBind releases 800 protein-ligand binding measurements and a free predictive model — the first serious public-sector attempt to build the PDB equivalent for drug-protein interactions. Also: the FDA ran 46 AI-triage one-day inspections before anyone announced the program, Novo Nordisk bets its recovery on an enterprise-wide OpenAI partnership, and Insilico's MMAI data makes the clearest empirical case yet that general LLMs simply don't work for drug discovery.
Isomorphic Labs gears up for human trials, Owkin's "AI scientist" lands at three top-ten pharmas, and Bessemer makes the case that biology-native data is the only durable advantage.
Isomorphic Labs starts moving AI-designed molecules into humans, and the read on the timeline tells you more about pharma's feedback loops than the model itself. Plus Owkin going agentic at scale and a Bessemer thesis worth taking seriously.
Eli Lilly's record partnership with Insilico Medicine is the largest AI drug-discovery deal in history. Why now, what it actually buys, and what the second-derivative effects are.
Lilly committed $2.75 billion to Insilico Medicine — the biggest AI drug-discovery deal so far. Insilico's platform has compressed certain discovery timelines from years to months, validated by rentosertib's clinical readouts in pulmonary fibrosis. The deal also reframes who gets to call themselves AI-first.